You are required to be logged in to access the full website
Click here if you have forgotten your username or password
People
Haas Named to Ligand Pharmaceuticals Board of Directors
30 June 2022 - - US-based biopharmaceutical company Ligand Pharmaceuticals Inc. (NASDAQ: LGND) has appointed Jason Haas to its board of directors, the company said.
Haas brings more than 30 years of healthcare investment banking and corporate finance experience to Ligand.
Haas is currently the CFO of Syros Pharmaceuticals, a NASDAQ listed biotech company focused on developing oncology therapeutics.
Prior to Syros, Haas spent over 25 years in healthcare investment banking where he executed many strategic transactions and supported companies through equity and debt financings, mergers and acquisitions, divestures, and spin-offs.
Haas served as Co-Head of Americas Healthcare Banking at Barclays, Head of Healthcare Investment Banking, Americas at Deutsche Bank and Managing director of Healthcare Investment Banking at Goldman Sachs.
Haas holds an M.B.A. in Finance from Columbia Business School and an A.B. in International Relations and Economics from Colgate University.
Ligand is a revenue-generating biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines.
Haas brings more than 30 years of healthcare investment banking and corporate finance experience to Ligand.
Haas is currently the CFO of Syros Pharmaceuticals, a NASDAQ listed biotech company focused on developing oncology therapeutics.
Prior to Syros, Haas spent over 25 years in healthcare investment banking where he executed many strategic transactions and supported companies through equity and debt financings, mergers and acquisitions, divestures, and spin-offs.
Haas served as Co-Head of Americas Healthcare Banking at Barclays, Head of Healthcare Investment Banking, Americas at Deutsche Bank and Managing director of Healthcare Investment Banking at Goldman Sachs.
Haas holds an M.B.A. in Finance from Columbia Business School and an A.B. in International Relations and Economics from Colgate University.
Ligand is a revenue-generating biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines.
Login
Related Headlines
Vial adds Dr Neeraj Agarwal to scientific advisor for Oncology CRO
Grey Wolf Therapeutics names new non-director to Australian subsidiary's board
Essenpreis Named to lino Biotech Board of Directors
West Pharmaceutical Services names new director